Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints

DOI10.1111/J.0006-341X.2004.00222.XMaRDI QIDQ3445296zbMATH OpenOpenAlexWikidataFDO

Authors Ariel Alonso, Geert Molenberghs, Tomasz Burzykowski, Helena Geys, Ziv Shkedy, Fabián S. Tibaldi, José Cortiñas Abrahantes, Marc Buyse, Didier Renard

Publication date 11 June 2007

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/j.0006-341x.2004.00222.x

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• A perspective on surrogate endpoints in controlled clinical trials
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
• The evaluation of surrogate endpoints.
• A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint
• Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

Cites work

• Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
• Information gain and a general measure of correlation
• Modelling Progression of CD4-Lymphocyte Count and Its Relationship to Survival Time
• On meta-analytic assessment of surrogate outcomes
• The validation of surrogate endpoints in meta-analyses of randomized experiments
• Validation of a longitudinally measured surrogate marker for a time-to-event endpoint

Cited in

(13)

• Use of the likelihood reduction factor in a path analysis framework to quantify surrogacy in clinical trials
• Proportion of treatment effect mediated by surrogate endpoints
• Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics
• Surrogate Marker Evaluation from an Information Theory Perspective
• Quantifying the Effect of the Surrogate Marker by Information Gain
• Center-within-trial versus trial-level evaluation of surrogate endpoints
• An information-theoretic approach to surrogate-marker evaluation with failure time endpoints
• Simplified modeling strategies for surrogate validation with multivariate failure-time data
• Statistical Methods for Clinical Studies in the Presence of Surrogate End Points
• A perspective on surrogate endpoints in controlled clinical trials
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
• Learning directed acyclic graphs by determination of candidate causes for discrete variables
• Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

This page was built for publication: Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3445296)